PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
A user is discussing their experience with finasteride for diffuse thinning without a receding hairline, noting a massive shedding phase in the fourth month that is now slowing down. Other replies are off-topic and not relevant to the treatment discussion.
A 19-year-old started Dutasteride at 17 to combat aggressive hair thinning, which halted his facial hair development despite having strong beard genetics. He also used oral and topical Minoxidil without success for facial hair, and the discussion highlights the impact of DHT blockers on beard growth.
The user experienced improved hair density and thickness after using finasteride and dermarolling for 2.5 years but noticed hair loss when doing anaerobic exercise. They increased their finasteride dose and continued dermarolling but are considering not starting minoxidil due to its perceived hassle and uncertain long-term benefits.
A user shared progress pictures showing hair improvement after 11 months of using finasteride, minoxidil, and occasional microneedling. The user aims to motivate others starting similar treatments.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
A 21-year-old experiencing aggressive hair shedding is considering treatments like Propecia (finasteride) and Rogaine (minoxidil) to slow or stop hair loss. Recommendations include using these treatments along with Nizoral Shampoo, hair vitamins, and a derma roller to maintain and potentially regrow hair.
The user is experiencing continued hair loss despite using minoxidil, finasteride, tretinoin, and microneedling. They are considering a hair transplant due to lack of response to current treatments.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.
Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.
The emotional and psychological impact of hair loss in young people, how to cope with it, and potential treatments such as finasteride, RU58841, Minoxidil, SMP, and hair transplants.
A trans man is experiencing hair loss due to testosterone therapy but is unwilling to stop the treatment despite concerns about using finasteride. The individual is distressed about balding at a young age but acknowledges it is genetic.
A 19-year-old is experiencing hair loss and has been using Rogaine for a month and finasteride for four days without improvement, while also experiencing testicular discomfort. They are concerned about losing hair density and potential DUPA, comparing their situation to their father's hair condition.
A 31-year-old male shared his 3-year progress using finasteride 1 mg daily, with additional treatments including nutrafol, multivitamins, vitamin D, marine collagen, PRP scalp injections, micro-needling, and Nizoral. He experienced temporary libido issues but currently has no side effects.
A 35-year-old male experiences rapid hair loss on his head and body despite normal test results for testosterone, thyroid, and vitamins. He previously used topical minoxidil and retinol, and doctors have been consulted without finding a clear cause.
A man in his 40s treating his slow balding with a daily regimen of 2.5% spironolactone topical solution and Piroctone Olamine Shampoo. Despite initial hair shedding, he experienced no side effects and plans to continue the treatment for at least a year.
A 24-year-old noticed hair thinning over 4-6 years and is seeking advice on whether it can be salvaged. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The post discusses a user's hair loss treatment routine, which includes daily 1mg finasteride, twice daily topical rogaine, biotin vitamin intake, and a new microneedling regimen of 0.5mm three times a week. The user is turning 24 next month.
A 17-year-old is concerned about hair thinning and unable to see a dermatologist for a year. They are advised to consider using topical minoxidil and possibly finasteride in the future.
A 17-year-old shares their hair loss treatment, using oral finasteride, dutasteride, stemoxydine, alfatradiol, and a placebo product, but cannot use minoxidil due to an allergic reaction. Others discuss similar treatments and question the use of dutasteride at a young age.
A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.
The conversation is a satirical discussion about a baby with hair loss using adult hair loss treatments like finasteride, minoxidil, and ketoconazole, as well as dermarolling, scalp massages, and plans for PRP sessions. Suggestions include various other treatments and humorous advice, reflecting the satire of the situation.
The user is experiencing hair loss and is using treatments like finasteride, minoxidil, and hormone replacement therapy (estradiol enanthate injections) to address it. They are advised to be patient with the treatments and consider using a dermapen for microneedling.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.